Erratum: Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial (Inflamm Bowel Dis. (2016) 22 (638–647) DOI: 10.1097/MIB.0000000000000615);Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial

Inflammatory Bowel Diseases

Volumn 22, Issue 3, 2016, Pages 638-647

  Debruyn, Jennifer ^a   Fonseca, Kevin ^b   Ghosh, Subrata ^c   Panaccione, Remo ^c   Gasia, Miriam F ^c   Ueno, Aito ^c   Kaplan, Gilaad G ^c   Seow, Cynthia H ^c   Wrobel, Iwona ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Provincial Laboratory of Public Health   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

immune response; Inflammatory bowel disease; infliximab; influenza vaccine

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; BLOOD; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 84959364238     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000915     Document Type: Erratum

References (36)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54.
2. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressant and biologics for inducing and Maintaining remission in Crohn's disease: a Network meta-analysis. Gastroenterology. 2015;148: 344-354.
3. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following antitumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896.
4. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52:3403.
5. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10: 677-692.
6. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009; 15:1410-1416.
7. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8: 443-468.
8. Schanzer DLM, Langley JMM, Tam TWSM. Hospitalization Attributable to influenza and other viral respiratory Illnesses in Canadian children. Pediatr Infect Dis J. 2006;25:795-800.
9. Schanzer DL, Langley JM, Tam TWS. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respir Viruses. 2008;2:1-8.
10. Kwong JC. Evaluation of the Effect of Ontario's Universal Influenza Immunization Program (UIIP). Ottawa, Canada: Public Health Agency of Canada, Catalogue HP40-34/2008E-PDF; 2008.
11. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102:2-9.
12. Billings JL, Hertz MI, Savik K, et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559-566.
13. Hassan IA, Chopra R, Swindell R, et al. Respiratory viral infections after bone marrow/peripheral stem-cell transplantation: the Christie hospital experience. Bone Marrow Transplant. 2003;32:73-77.
14. Statement on seasonal trivalent inactivated influenza vaccine for 2011-2012. Can Commun Dis Rep. 2011;37. ACS-5. Available at: http://www.phacaspc. gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-5/index-eng.php. Accessed January 25, 2012.
15. Centers for Disease Control and Prevention. Preventing seasonal flu with vaccination. Available at: http://www.cdc.gov/flu/protect/vaccine/index. htm. Accessed January 24, 2012.
16. Fiore AE, Bridges CB, Cox NJ. Seasonal influenza vaccines. Curr Top Microbiol Immunol. 2009;333:43-82.
17. Palmer DF, Dowdle WR, Coleman MT, et al. Haemagglutination-inhibition test. In: Advanced Laboratory Techniques for Influenza Diagnosis. Procedural Guide. Atlanta, GA: US Department of Health and Welfare; 1975:25-62.
18. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851-856.
19. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104:444-453.
20. deBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:25-33.
21. Hiroko M, Watanabe K, Morimoto K, et al. Booster doses of the trivalent influenza vaccine do not elicit a significant immune response in patients with inflammatory bowel disease: a prospective randomized controlled trial. Gastroenterology. 2014;146(suppl 1):5-80.
22. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
23. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423-432.
24. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081-1088.
25. Adverse reactions. In: Vaccinations and Communicable Disease Control. Calgary, Canada: Calgary Health Region; 2004:1-13.
26. Kendal AP, Pereira MS, Shekel J. Concepts and Procedures for Laboratory-based Influenza Surveillance. Geneva, Switzerland: World Health Organization; 1982.
27. Beyer WE, Palache AM, de Jong JC, et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002;20:1340-1353.
28. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67:713-716.
29. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010;39:442-447.
30. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982;3:345-353.
31. Kapetanovic MC, Saxne T, Nilsson JA, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007;46:608-611.
32. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65:191-194.
33. Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations A systematic review. Vaccine. 2012;30:1413-1424.
34. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med. 1996;156:1546-1550.
35. Bolge SC, Waters H, Piech CT. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey. Clin Ther. 2010;32:238-245.
36. Benchimol EI, Hawken S, Kwong JC, et al. Safety and utilization of influenza immunization in children with inflammatory bowel disease. Pediatrics. 2013;131:e1811-e1820.